StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mallinckrodt (MNK) Reports Negative FDA Advisory Committee Vote on Stannsoporfin for Treatment of Newborns at Risk of Developing Severe Jaundice
May 4, 2018 6:21 AM
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today expressed disappointment that, in a joint meeting, the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
Mallinckrodt (MNK) Tops Q1 EPS by 22c, Beats on Revenues
May 8, 2018 6:11 AM
Mallinckrodt (MNK) Seen as Target of Negative Upcoming 60 Minutes Episode
May 4, 2018 10:06 AM
Mallinckrodt Reports on FDA Joint Advisory Committee Meeting for Stannsoporfin for the Treatment of Newborns at Risk of Developing Severe Jaundice
May 3, 2018 6:49 PM
Mallinckrodt (MNK) Weakness Tied to FDA Panel Review
May 3, 2018 2:36 PM
Mallinckrodt (MNK) Active, Shares Decline
May 3, 2018 2:32 PM
